Download this assay page in pdf format.
Analyte: Glucagon-Like Peptide 1 Total
Specimen Type: Plasma from BD P700 or P800, EDTA Plasma with preservatives; contact PBI for collection instructions
Optimum Volume: 0.5 mL
|6 hours||6 months||2.8 years|
Reporting units: pmol/L
Biological or Clinical Significance:
Glucagon-like peptide 1 (GLP-1) is a 3.5 kD incretin hormone secreted primarily from the enteroglucagon-producing L-cells in the small intestine. It is released in response to a meal and is highly potent in stimulating insulin and inhibiting glucagons secretion. GLP-1 (7-36) amide and GLP-1 (7-37) are the biologically active forms of GLP-1. In vivo, the active forms are rapidly degraded by the dipeptidyl peptidase IV (DPP-IV).
Principle of Test Method:
The GLP-1 total asay is an ultra-sensitive kit designed to quantify human total GLP-1 in human plasma, serum, and other biological media. This immunoassay employs electrochemilunimescent detection.
1. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Egan JM. Human duodenal enteroendocrine cells: Source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab. 2006; 290: E550-559.
2. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an n-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957.
3. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004; 53:654-662.
4. Kim BJ, Carlson OD, Jang HJ, Elahi D, Berry C and Egan JM. Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab 2005, 90: 6665-6671